Every 10-Q that Karyopharm Therapeutics Inc (KPTI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow KPTI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KPTI filings page.
Karyopharm Therapeutics reported total revenue of $68.5 million for the six months ended June 30, 2026, roughly flat versus 2025, with XPOVIO net product revenue rising to $59.9 million and license and other revenue declining to $8.6 million. Operating loss narrowed to $49.3 million, but a sharp increase in other expense led to a net loss of $89.4 million versus $60.7 million a year earlier.
Cash, cash equivalents and investments totaled $65.1 million, while total liabilities were $441.5 million, including a senior secured term loan of $125.4 million, New 2029 Notes of $98.7 million, 2028 Notes of $25.9 million, a $72.3 million deferred royalty obligation and warrant liabilities. Stockholders’ deficit widened to $(330.2) million. The company expects its current liquidity plus anticipated revenues to fund operations only into September 2026 and discloses substantial doubt about its ability to continue as a going concern.
A $15.8 million term-loan principal payment is due September 10, 2026, plus about $10.1 million of interest across its debt on September 30, 2026; management warns it may be unable to fund operations after these payments without new financing or strategic transactions and may need to consider bankruptcy. Clinically, the Phase 3 SENTRY trial in myelofibrosis met its spleen-volume endpoint but not symptom improvement, and Karyopharm plans an August 2026 sNDA seeking accelerated approval for selinexor plus ruxolitinib. A separate Phase 3 endometrial cancer study did not meet its primary endpoint, and the DLBCL indication for XPOVIO is being voluntarily withdrawn.
Karyopharm Therapeutics reported a Q1 2026 net loss of $22.4 million on total revenue of $35.1 million, up from $30.0 million a year earlier. Product revenue from XPOVIO rose to $29.2 million, while license and other revenue declined to $5.9 million.
The company ended the quarter with $90.9 million in cash and cash equivalents and total assets of $131.4 million against total liabilities of $397.1 million, leaving a stockholders’ deficit of $265.6 million and an accumulated deficit of $1.8 billion.
Management concludes there is substantial doubt about the ability to continue as a going concern within one year, given ongoing losses, significant debt, required minimum liquidity covenants, and uncertainty around new funding or strategic alternatives. Recent financing included $26.9 million from a private placement and $19.8 million from at-the-market share sales, plus amendments and forbearance on term loan and convertible notes.
Karyopharm Therapeutics (KPTI) reported Q3 2025 results and flagged substantial doubt about continuing as a going concern. Revenue was $44.0 million (product $32.0 million; license/other $12.0 million, including Menarini milestones). Operating expenses fell year over year, but the company posted a net loss of $33.1 million and interest expense of $11.0 million in the quarter.
As of September 30, cash, cash equivalents and investments totaled $45.9 million. The balance sheet shows a senior secured term loan of $100.0 million, $116.0 million of 2029 convertible notes (principal), and a $73.5 million deferred royalty obligation. Management cited debt service, a minimum liquidity covenant and uncertain funding access in concluding there is substantial doubt about the company’s ability to continue as a going concern.
Subsequent to quarter-end (October 2025), the company executed financing transactions that included $27.5 million of new borrowings/convertible debt, $25.4 million of near-term payment deferrals, a temporary $15.0 million reduction of the minimum liquidity covenant, exchanges of 2025/2029 notes into equity and warrants, and a private placement raising ~$8.8 million.
Karyopharm Therapeutics (KPTI) reported total revenue of $37.9 million for the quarter and $67.9 million year-to-date, driven primarily by U.S. product sales of XPOVIO (net product revenue of $29.7 million in Q2). The company recorded a net loss of $37.3 million for the quarter and $60.7 million for the six months ended June 30, 2025. Cash and short-term investments totaled approximately $51.7 million at June 30, 2025, while total assets were $104.9 million against $343.8 million of liabilities, resulting in a stockholders' deficit of $238.9 million.
The balance sheet shows near-term funding pressures: convertible 2025 Notes of $24.5 million mature October 15, 2025; a $100.0 million senior secured Term Loan (carrying $95.8 million) matures May 2028; and 2029 Notes (principal $116.0 million, carrying $62.7 million) mature in 2029. Management discloses "substantial doubt" about the company’s ability to continue as a going concern within one year and is evaluating strategic and financing alternatives; the company reduced headcount by ~20% as part of cost management.